drugset / Trial / NCT03527108
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
Phase 2
Active not recruiting
36 enrolled
Fox Chase Cancer Center
Bristol-Myers Squibb · collabEli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment
Summary
The study will enroll patients with prior IO therapy (alone or in combination with chemotherapy or in combination with other IO agents) regardless of the PD-L1 level, into a non-randomized combination trial, with primary endpoint of disease control rate.
Timeline
- Start
- 2020-10-08
- Primary completion
- 2026-12
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 240 mg | — |
| Subject | Ramucirumab | Monoclonal antibody | — | — |